Report of Foreign Issuer (6-k)
October 17 2017 - 5:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
October 2017
Commission file number: 001-36288
Akari
Therapeutics, Plc
(Translation of registrant's name into English)
24 West 40
th
Street, 8
th
Floor
New York, NY 10018
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On October 17, 2017,
Akari Therapeutics, Plc (the “Company”), announced that it intended to make a public offering of its American Depositary
Shares.
In connection with
this proposed offering, the Company prepared a description of certain risk factors relating to the Company, its business and industry
and other information that are being presented to potential investors. These risk factors and updated business and industry and
other information update the risk factors, business and industry and other information included in the Company's Annual Report
on Form 20-F for the fiscal year ended December 31, 2016, which was filed with the Securities and Exchange Commission (the “SEC”)
on March 31, 2017.
The risk factors and
updated business and industry and other information are attached hereto as Exhibit 99.1 and incorporated by reference herein. The
offering is being made pursuant to an effective registration statement filed with the SEC. Before investing, please read the prospectus
and the related prospectus supplement for the offered ADSs in the registration statement and other documents the Company has filed
with the SEC for more complete information about the Company and the proposed offering.
This report shall
not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities law of any such state or jurisdiction.
The information contained
in this report (including the exhibit hereto) is hereby incorporated by reference into all effective registration statements filed
by the Company under the Securities Act of 1933.
|
Exhibit No.
|
|
|
|
|
|
|
|
99.1
|
|
Risk Factor, Business
and Industry and Other Information update dated October 17, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Robert M. Shaw
|
|
|
Name:
|
Robert M. Shaw
|
|
|
|
General Counsel & Secretary
|
Date: October 17, 2017
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
